260 related articles for article (PubMed ID: 33431157)
1. Economic Benefits of Immunization for 10 Pathogens in 94 Low- and Middle-Income Countries From 2011 to 2030 Using Cost-of-Illness and Value-of-Statistical-Life Approaches.
Watts E; Sim SY; Constenla D; Sriudomporn S; Brenzel L; Patenaude B
Value Health; 2021 Jan; 24(1):78-85. PubMed ID: 33431157
[TBL] [Abstract][Full Text] [Related]
2. Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030.
Sim SY; Watts E; Constenla D; Huang S; Brenzel L; Patenaude BN
Value Health; 2021 Jan; 24(1):70-77. PubMed ID: 33431156
[TBL] [Abstract][Full Text] [Related]
3. Costs of vaccine programs across 94 low- and middle-income countries.
Portnoy A; Ozawa S; Grewal S; Norman BA; Rajgopal J; Gorham KM; Haidari LA; Brown ST; Lee BY
Vaccine; 2015 May; 33 Suppl 1():A99-108. PubMed ID: 25919184
[TBL] [Abstract][Full Text] [Related]
4. What We Do Not Know About the Costs of Immunization Programs in Low- and Middle-Income Countries.
Portnoy A; Resch SC; Suharlim C; Brenzel L; Menzies NA
Value Health; 2021 Jan; 24(1):67-69. PubMed ID: 33431155
[TBL] [Abstract][Full Text] [Related]
5. Effect of donor funding for immunization from Gavi and other development assistance channels on vaccine coverage: Evidence from 120 low and middle income recipient countries.
Ikilezi G; Augusto OJ; Dieleman JL; Sherr K; Lim SS
Vaccine; 2020 Jan; 38(3):588-596. PubMed ID: 31679863
[TBL] [Abstract][Full Text] [Related]
6. Estimated economic impact of vaccinations in 73 low- and middle-income countries, 2001-2020.
Ozawa S; Clark S; Portnoy A; Grewal S; Stack ML; Sinha A; Mirelman A; Franklin H; Friberg IK; Tam Y; Walker N; Clark A; Ferrari M; Suraratdecha C; Sweet S; Goldie SJ; Garske T; Li M; Hansen PM; Johnson HL; Walker D
Bull World Health Organ; 2017 Sep; 95(9):629-638. PubMed ID: 28867843
[TBL] [Abstract][Full Text] [Related]
7. Projections of costs, financing, and additional resource requirements for low- and lower middle-income country immunization programs over the decade, 2011-2020.
Gandhi G; Lydon P; Cornejo S; Brenzel L; Wrobel S; Chang H
Vaccine; 2013 Apr; 31 Suppl 2():B137-48. PubMed ID: 23598475
[TBL] [Abstract][Full Text] [Related]
8. Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011-30.
Sim SY; Watts E; Constenla D; Brenzel L; Patenaude BN
Health Aff (Millwood); 2020 Aug; 39(8):1343-1353. PubMed ID: 32744930
[TBL] [Abstract][Full Text] [Related]
9. Estimating total spending by source of funding on routine and supplementary immunisation activities in low-income and middle-income countries, 2000-17: a financial modelling study.
Ikilezi G; Micah AE; Bachmeier SD; Cogswell IE; Maddison ER; Stutzman HN; Tsakalos G; Brenzel L; Dieleman JL
Lancet; 2021 Nov; 398(10314):1875-1893. PubMed ID: 34742369
[TBL] [Abstract][Full Text] [Related]
10. Return On Investment From Childhood Immunization In Low- And Middle-Income Countries, 2011-20.
Ozawa S; Clark S; Portnoy A; Grewal S; Brenzel L; Walker DG
Health Aff (Millwood); 2016 Feb; 35(2):199-207. PubMed ID: 26858370
[TBL] [Abstract][Full Text] [Related]
11. Trends in vaccine investment in middle income countries.
Onishchenko K; Hill S; Wasserman M; Jones C; Moffatt M; Ruff L; Pugh SJ
Hum Vaccin Immunother; 2019; 15(10):2378-2385. PubMed ID: 30843757
[TBL] [Abstract][Full Text] [Related]
12. Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.
Peny JM; Gleizes O; Covilard JP
Vaccine; 2005 Aug; 23(37):4610-8. PubMed ID: 15979769
[TBL] [Abstract][Full Text] [Related]
13. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.
Wolfson LJ; Gasse F; Lee-Martin SP; Lydon P; Magan A; Tibouti A; Johns B; Hutubessy R; Salama P; Okwo-Bele JM
Bull World Health Organ; 2008 Jan; 86(1):27-39. PubMed ID: 18235887
[TBL] [Abstract][Full Text] [Related]
14. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
[TBL] [Abstract][Full Text] [Related]
15. What have we learned on costs and financing of routine immunization from the comprehensive multi-year plans in GAVI eligible countries?
Brenzel L
Vaccine; 2015 May; 33 Suppl 1():A93-8. PubMed ID: 25919183
[TBL] [Abstract][Full Text] [Related]
16. Assessing the incremental costs and savings of introducing electronic immunization registries and stock management systems: evidence from the better immunization data initiative in Tanzania and Zambia.
Mvundura M; Di Giorgio L; Vodicka E; Kindoli R; Zulu C
Pan Afr Med J; 2020; 35(Suppl 1):11. PubMed ID: 32373262
[TBL] [Abstract][Full Text] [Related]
17. Country Ownership And Gavi Transition: Comprehensive Approaches To Supporting New Vaccine Introduction.
Shen AK; Weiss JM; Andrus JK; Pecenka C; Atherly D; Taylor K; McQuestion M
Health Aff (Millwood); 2016 Feb; 35(2):272-6. PubMed ID: 26858380
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of the costs and effectiveness of interventions to increase infant vaccination coverage in low- and middle-income countries.
Munk C; Portnoy A; Suharlim C; Clarke-Deelder E; Brenzel L; Resch SC; Menzies NA
BMC Health Serv Res; 2019 Oct; 19(1):741. PubMed ID: 31640687
[TBL] [Abstract][Full Text] [Related]
19. Vaccine Assistance To Low- And Middle-Income Countries Increased To $3.6 Billion In 2014.
Haakenstad A; Birger M; Singh L; Liu P; Lim S; Ng M; Dieleman JL
Health Aff (Millwood); 2016 Feb; 35(2):242-9. PubMed ID: 26858376
[TBL] [Abstract][Full Text] [Related]
20. Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity.
Stack ML; Ozawa S; Bishai DM; Mirelman A; Tam Y; Niessen L; Walker DG; Levine OS
Health Aff (Millwood); 2011 Jun; 30(6):1021-8. PubMed ID: 21653952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
